Novartis AG, AbbVie Inc., and Janssen Pharmaceuticals, Inc. (a subsidiary of Johnson & Johnson Services, Inc.) are Dominating the China Palmoplantar Pustulosis (PPP) Market in 2019

China Palmoplantar Pustulosis (PPP) Market is expected to grow with the CAGR of 5.1% in the forecast period of 2020 to 2027. The years considered for study are as mentioned below.

Access Full Report @

China palmoplantar pustulosis (PPP) market is a highly consolidated market, which includes specific number of key players. The market has witnessed increased strategic developments owing to favourable market scenario.   

The major players dealing in China palmoplantar pustulosis (PPP) market are introducing strong range of products provider along with launching new products and adopting strategic initiative such as acquisition, agreement into the market. This helped companies to maximize the sales with enhanced product portfolio. For instance, in March 2020, Amgen Inc. established a new subsidiary in Japan for enhancing product manufacturing and distribution capabilities. Japan patients require innovative medicines to treat various kinds of inflammatory diseases involving palmoplantar pustulosis among others. This expansion thus allowed the company to enhance its overall revenue by enhancing product sales.

Novartis AG is the dominating player in China palmoplantar pustulosis (PPP) market. The other key players existing in the market includes Novartis AG, Eli Lilly and Company, Boehringer Ingelheim International GmbH, Amgen Inc., Janssen Pharmaceuticals, Inc.  (A Subsidiary of Johnson & Johnson Services, Inc.), AbbVie Inc., Bristol-Myers Squibb Company, Perrigo Company plc, ingenus Pharmaceuticals, F. Hoffmann-La Roche Ltd, WOCKHARDT, Bausch Health Companies Inc., ALEOR Dermaceuticals Limited, Mylan N.V., Amneal Pharmaceuticals LLC., Xiromed, Encube Ethicals, among others.

China Palmoplantar Pustulosis (PPP) Market

Novartis AG

Novartis AG was founded in 1996. The company headquarter is in Basel, Switzerland. The company focuses on innovating new solutions for various health care challenges. The company business segment is innovative medicines, Sandoz. The company is engaged in providing products in categories like cancer, cardiovascular, renal & metabolism, immunology & dermatology, ophthalmology, neuroscience, respiratory, immunology & dermatology the market focused category.

For instance,

  • In January 2019, Novartis AG obtained positive results from different clinical trials phases conducted under Phase 3. The result obtained suggested that Cosentyx can treat patients with moderate to severe plaque psoriasis, the disease which involves the formation of pustules in affected body parts. The result obtained allowed the company to penetrate its root in the palmoplantar pustulosis market.

The company has wide presence across Americas, Asia-Pacific, Europe/Middle East/Africa. The company has various subsidiary companies such as Novartis Argentina S.A., Buenos Aires (Argentina), Novartis Australia Pty Ltd, Macquarie Park, NSW (Australia), Novartis Austria GmbH, Vienna(Austria), Novartis Pharma NV, Vilvoorde (Belgium) and Sandoz (China) Pharmaceutical (China) among others. The company has initiated many strategic initiatives to expand its market.

AbbVie Inc.

AbbVie Inc. headquartered in North Chicago, Illinois, U.S.A., was incorporated in 2013. The company is a research-driven biopharmaceutical company having a great focus on treating diseases in order to make a remarkable impact on people's lives. The company has multiple business segments such as   immunology, hematologic oncology, HCV, other key products. In which the market focused segment is immunology. The company is various products involving AndroGel (testosterone gel), CREON (pancrelipase) Delayed-Release Capsules, Depakote (divalproex sodium) tablets, GENGRAF Capsules (cyclosporine capsules, USP), GENGRAF Oral Solution (cyclosporine oral solution, USP), DUOPA (carbidopa/levodopa enteral suspension), HUMIRA (adalimumab), KALETRA (lopinavir/ritonavir) Tablets and KALETRA (lopinavir/ritonavir) Oral Solution, LUPRON DEPOT (leuprolide acetate for depot suspension) URO, MAVYRET (glecaprevir/pibrentasvir), NORVIR Tablets (ritonavir tablets/oral solution), ORILISSA (elagolix) tablets, TARKA (trandolapril/verapamil HCI ER) among others, in which GENGRAF Capsules (cyclosporine capsules, USP), GENGRAF Oral Solution (cyclosporine oral solution, USP), HUMIRA (adalimumab) are market focused products.

For instance,

  • In May 2019, AbbVie Inc. resolved the litigation associated with Boehringer Ingelheim (BI) regarding HUMIRA, a adalimumab indicated for treatment of various kinds of inflammatory conditions. As per this resolution agreement, AbbVie Inc. will grant Boehringer Ingelheim (BI) a nonexclusive license for HUMIRA-related intellectual property in the United States, which allowed the company to expand its market in the U.S.

The company has wide presence across Africa, Asia-Pacific, Europe, Latin America, Middle East, North America, and South America. The company also has various subsidiary companies such as Knoll Pharmaceutical Company (New Jersey), AbbVie S.A. (Argentina), AbbVie Pty Ltd (Australia), AbbVie SA (Belgium) and AbbVie SAS (Colombia), among others.

Janssen Pharmaceuticals, Inc. (A Subsidiary of Johnson & Johnson Services, Inc.)

Janssen Pharmaceuticals, Inc. (A Subsidiary of Johnson & Johnson Services, Inc.) was incorporated in 1961 and is headquartered in New Jersey, U.S. The company is focused on providing innovative solutions for most of the devastating disease in various therapeutic areas involving cardiovascular, immunology among others. The company business segment is pharmaceuticals, consumer, medical Devices. The company operates its business through pharmaceuticals, consumer, medical devices business segments in which pharmaceuticals is the market focused segment. The company is providing products under cardiovascular & metabolism, immunology, infectious diseases & vaccines, neuroscience, oncology, other product categories. The market’s focused products lie under immunology category.

For instance,

  • In December 2018, Janssen Pharmaceuticals, Inc. (A Subsidiary of Johnson & Johnson Services, Inc.) submitted supplemental biologics application for STELARA (ustekinumab), a drug indicated to target and inhibits the IL-23 cytokines, which gets activated during the palmoplantar pustulosis. This application submission proved to be the important initiative taken by the company in order to evolve itself in the palmoplantar pustulosis market.

The company has wide presence across the America, Europe, Middle East & Africa, Asia-Pacific. The company has various subsidiary companies involving Janssen-Cilag A/S (Denmark), Janssen Pharmaceutica (Pty.) Ltd. (South Africa), Johnson & Johnson del Perú SA (Peru), Janssen-Cilag Farmacêutica Ltda. (Brazil) and Janssen Pharmaceuticals, Inc. (U.S.), among others.